Key Record Dates
ClinicalTrials.gov Identifier: | NCT05211895 |
---|---|
Brief Title: | A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8) |
First Submitted : | January 11, 2022 |
First Submitted that Met QC Criteria : | January 26, 2022 |
First Posted : | January 27, 2022 |
Last Update Submitted that Met QC Criteria : | April 18, 2024 |
Last Update Posted : | April 19, 2024 |